Featuring Michael F. Cannon, Director of Health Policy Studies, Cato Institute; and Jonathan H. Adler, Johan Verheij Memorial Professor of Law; Director, Center for Business Law and Regulation, Case Western Reserve University School of Law; moderated by John Maniscalco, Director of Congressional Affairs, Cato Institute.
Featuring Roger Pilon, Vice President for Legal Affairs, Cato Institute.
Drug reimportation looks “inevitable,” said Health and Human Services Secretary Tommy Thompson in May. Last year the House overwhelmingly passed a bill lifting the federal ban on reimporting prescription drugs, and three such bills are now pending in the Senate. Several state and local officials, defying federal law, have begun their own reimportation programs. John Kerry supports reimportation. And President Bush recently signaled he would reconsider the issue if drug safety can be ensured. Something is going to give.
In his recent Cato study, Roger Pilon has taken an in-depth look at this complex issue and concluded that lifting the reimportation ban is the right answer, even if bills currently in Congress don’t always do it the right way. Please join us for a broad discussion of an issue that is sure to be on Congress’s plate until it is resolved.